Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer.
COVID-19
anxiety
cancer worry
coronavirus
depression
ovarian cancer
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
01
05
2020
revised:
12
06
2020
accepted:
23
06
2020
pubmed:
1
7
2020
medline:
13
11
2020
entrez:
30
6
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 pandemic has resulted in unprecedented challenges for the oncology community. For people living with cancer, treatments are interrupted, surgeries cancelled, and regular oncology evaluations rescheduled. People with cancer and their physicians must balance plausible fears of coronavirus disease 2019 and cancer treatment with the consequences of delaying cancer care. We aim to evaluate the experience of women with ovarian cancer during the coronavirus disease 2019 pandemic. Women with a current or previous diagnosis of ovarian cancer completed an online survey focusing on treatment interruptions and quality of life. The quality of life was measured with the Cancer Worry Scale and Hospital Anxiety and Depression Scale. The survey was distributed through survivor networks and social media. Univariate and multivariable linear regression analysis were used to evaluate the effect of participant characteristics on quality of life survey scores. A total of 603 women, from 41 states, visited the survey website between March 30, 2020, and April 13, 2020, and 555 (92.0%) completed the survey. The median age was 58 years (range, 20-85). At the time of survey completion, 217 participants (43.3%) were in active treatment. A total of 175 participants (33%) experienced a delay in some component of their cancer care. Ten (26.3%) of the 38 participants scheduled for surgery experienced a delay, as did 18 (8.3%) of the 217 participants scheduled for nonsurgical cancer treatment. A total of 133 participants (24.0%) had a delayed physician appointment, 84 (15.1%) laboratory tests, and 53 (9.6%) cancer-related imaging. Among the cohort, 88.6% (489) reported significant cancer worry, 51.4% (285) borderline or abnormal anxiety, and 26.5% (147) borderline or abnormal depression. On univariate analysis, age less than 65 years, being scheduled for cancer treatment or cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine were all associated with higher levels of cancer worry. Higher anxiety scores were associated with age less than 65 years and being self-described as immunocompromised. Higher depression scores were associated with age less than 65 years, being scheduled for cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine. On multivariable linear regression analysis, age less than 65 and being self-described as immunocompromised were independently predictive of greater cancer worry, anxiety, and depression, and delay in cancer care was predictive of anxiety and depression. The coronavirus disease 2019 crisis is affecting care of patients with ovarian cancer; surgeries, treatments, scheduled physician appointments, laboratory tests, and imaging are cancelled or delayed. Younger age, presumed immunocompromise, and delay in cancer care were associated with significantly higher levels of cancer worry, anxiety, and depression. Providers must work with patients to balance competing risks of coronavirus disease 2019 and cancer, recognizing that communication is a critical clinical tool to improve quality of life in these times.
Sections du résumé
BACKGROUND
The coronavirus disease 2019 pandemic has resulted in unprecedented challenges for the oncology community. For people living with cancer, treatments are interrupted, surgeries cancelled, and regular oncology evaluations rescheduled. People with cancer and their physicians must balance plausible fears of coronavirus disease 2019 and cancer treatment with the consequences of delaying cancer care.
OBJECTIVE
We aim to evaluate the experience of women with ovarian cancer during the coronavirus disease 2019 pandemic.
STUDY DESIGN
Women with a current or previous diagnosis of ovarian cancer completed an online survey focusing on treatment interruptions and quality of life. The quality of life was measured with the Cancer Worry Scale and Hospital Anxiety and Depression Scale. The survey was distributed through survivor networks and social media. Univariate and multivariable linear regression analysis were used to evaluate the effect of participant characteristics on quality of life survey scores.
RESULTS
A total of 603 women, from 41 states, visited the survey website between March 30, 2020, and April 13, 2020, and 555 (92.0%) completed the survey. The median age was 58 years (range, 20-85). At the time of survey completion, 217 participants (43.3%) were in active treatment. A total of 175 participants (33%) experienced a delay in some component of their cancer care. Ten (26.3%) of the 38 participants scheduled for surgery experienced a delay, as did 18 (8.3%) of the 217 participants scheduled for nonsurgical cancer treatment. A total of 133 participants (24.0%) had a delayed physician appointment, 84 (15.1%) laboratory tests, and 53 (9.6%) cancer-related imaging. Among the cohort, 88.6% (489) reported significant cancer worry, 51.4% (285) borderline or abnormal anxiety, and 26.5% (147) borderline or abnormal depression. On univariate analysis, age less than 65 years, being scheduled for cancer treatment or cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine were all associated with higher levels of cancer worry. Higher anxiety scores were associated with age less than 65 years and being self-described as immunocompromised. Higher depression scores were associated with age less than 65 years, being scheduled for cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine. On multivariable linear regression analysis, age less than 65 and being self-described as immunocompromised were independently predictive of greater cancer worry, anxiety, and depression, and delay in cancer care was predictive of anxiety and depression.
CONCLUSION
The coronavirus disease 2019 crisis is affecting care of patients with ovarian cancer; surgeries, treatments, scheduled physician appointments, laboratory tests, and imaging are cancelled or delayed. Younger age, presumed immunocompromise, and delay in cancer care were associated with significantly higher levels of cancer worry, anxiety, and depression. Providers must work with patients to balance competing risks of coronavirus disease 2019 and cancer, recognizing that communication is a critical clinical tool to improve quality of life in these times.
Identifiants
pubmed: 32598911
pii: S0002-9378(20)30674-8
doi: 10.1016/j.ajog.2020.06.049
pmc: PMC7318934
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
725.e1-725.e9Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Aust N Z J Obstet Gynaecol. 2009 Dec;49(6):660-6
pubmed: 20070719
Br J Health Psychol. 2004 Nov;9(Pt 4):569-81
pubmed: 15509362
Psychooncology. 2015 Feb;24(2):190-6
pubmed: 25044162
J Natl Compr Canc Netw. 2016 Apr;14(4):429-37
pubmed: 27059191
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Psychooncology. 2018 Jul;27(7):1810-1815
pubmed: 29644766
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Nat Med. 2020 Apr;26(4):458
pubmed: 32284617
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Gynecol Oncol. 2014 Nov;135(2):261-5
pubmed: 25230215
Med J Aust. 2010 Sep 6;193(S5):S52-7
pubmed: 21542447
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Racial Ethn Health Disparities. 2020 Jun;7(3):398-402
pubmed: 32306369
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Gynecol Oncol. 2017 Aug;146(2):386-391
pubmed: 28602549
Health Aff (Millwood). 2013 Jun;32(6):1143-52
pubmed: 23676531
Asia Pac J Oncol Nurs. 2015 Jul-Sep;2(3):160-168
pubmed: 27981110
Psychooncology. 2018 Nov;27(11):2609-2615
pubmed: 29843189
J Clin Oncol. 1994 Apr;12(4):843-50
pubmed: 8151327
J Clin Oncol. 2020 Jul 1;38(19):2206-2207
pubmed: 32267782
JCO Oncol Pract. 2020 Feb;16(2):e148-e154
pubmed: 31815575
Gynecol Oncol. 2020 Jul;158(1):25-31
pubmed: 32446719
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
Obstet Gynecol. 2017 Dec;130(6):1269-1275
pubmed: 29112648
Nat Commun. 2017 Jul 11;8:15964
pubmed: 28696410
J Natl Compr Canc Netw. 2017 Jul;15(7):872-877
pubmed: 28687575
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:85-91
pubmed: 28738296
Gynecol Oncol. 2007 Feb;104(2):381-9
pubmed: 17027072
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Gynecol Oncol. 2020 Jul;158(1):32-33
pubmed: 32402631
Eur J Cancer Care (Engl). 2007 Jan;16(1):33-8
pubmed: 17227351
J Psychosom Obstet Gynaecol. 2016;37(2):57-67
pubmed: 26939616